Striking at Survivin: YM-155 Inhibits High-Risk Neuroblastoma Growth and Enhances Chemosensitivity
Overall, our findings identify YM-155 as a promising therapeutic agent for high-risk NB by directly targeting survivin and enhancing chemosensitivity. These results support continued preclinical development of survivin inhibitors as part of rational combination strategies in pediatric cancer treatment.
Authors
- Danielle C. Rouse (ORCID: https://orcid.org/0000-0002-0723-4411)
- Rameswari Chilamakuri (ORCID: https://orcid.org/0000-0003-4938-7368)
- Saurabh Agarwal (ORCID: https://orcid.org/0000-0001-9758-6746)
Institutions
- St. John's University (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-02
- DOI
- https://doi.org/10.3390/cancers17193221
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- St. John's University